Qure.ai vs Viz.ai
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
|
|
Viz.ai
AI that flags suspected strokes on scans and pages the care team
Visit
|
|
|---|---|---|
| RECATOOLS Score | 8.2 / 10 | 8.2 / 10 |
| Capability | ||
| Value for money | ||
| Ease of use | ||
| ASEAN readiness | ||
| API quality | ||
| Pricing | Enterprise | Enterprise |
| Free tier | No free tier; enterprise contracts only; trial demos available via sales | — |
| Paid from | Custom enterprise pricing; contact sales for per-scan or site-licence quotes | Quoted on request (demo and sales contact only, no published price) |
| Has API | ✓ | ✓ |
| Open source | ✗ | ✗ |
| Free to use | ✗ | ✗ |
| Users | 34M+ lives impacted across 4,800+ clinical sites in 105+ countries (as of late 2025) | Nearly 2,000 U.S. hospitals; 60,000+ providers; 230M+ lives covered |
| Founded | 2016 | 2016 |
| Maker | Independent (Series D — Lightspeed, 360 ONE Asset, Merck GHI Fund) | Dr. Chris Mansi (CEO, neurosurgeon) and Dr. David Golan (CTO, machine learning researcher) |
| Verdict | Qure.ai is one of the most credentialled and widely deployed AI radiology platforms in the world, with a regulatory portfolio (26 FDA-cleared indications, Class IIb CE under EU MDR, CDSCO Class B in India, registrations... |
Viz.ai pioneered AI stroke triage, and its 2018 De Novo authorisation is still the reference point for the category. Today it is a broad care-coordination platform in about 2,000 US hospitals, with 13 FDA clearances behi... |
| Full review → | Full review → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.